NuCana plc
NuCana plc (NCNA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ncna · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NuCana plcYou NCNA | $13M | N/A | — | — |
 CASI Pharmaceuticals, Inc. CASI | $2M | N/A | — | -$2.56 |
 CollPlant Biotechnologies Ltd. CLGN | $5M | N/A | — | -$0.94 |
 Clearside Biomedical, Inc. CLSD | $2M | N/A | — | -$6.98 |
 Enlivex Therapeutics Ltd. ENLV | $18M | 0.03x | — | $27.04 |
 CytoMed Therapeutics Limited GDTC | $13M | N/A | — | -$0.34 |
 Lisata Therapeutics, Inc. LSTA | $31M | N/A | — | -$1.91 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NuCana plc (NCNA) measures how much investors pay for each dollar of the company's trailing earnings. NCNA's current PE ratio of N/A is calculated by dividing its stock price of $2.08 by its TTM earnings per share of —.
Frequently asked questions
NCNA pe ratio · 6 questionsNCNA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.08 and TTM EPS of —. Data sourced from Financial Modeling Prep via NCNA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NuCana plc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09